Gedeon Richter Updates Patient Information for Postinor® Emergency Contraceptive

Gedeon Richter Plc. has announced an update to the patient information leaflet for its emergency contraceptive product, Postinor® (levonorgestrel 0.75 mg, tablet). The revised leaflet offers important guidance for patients on the administration and efficacy of the medication.

Postinor® contains levonorgestrel, a synthetic form of progesterone, and is indicated for emergency contraception. It is designed to prevent pregnancy when taken within 72 hours after unprotected sexual intercourse or following the failure of a contraceptive method. The primary mechanism of action involves suppressing or delaying ovulation, or hindering fertilization if intercourse occurs close to the fertile period.

The updated information emphasizes that Postinor® is most effective when taken as soon as possible after unprotected intercourse, ideally within the first 12 hours, and no later than 72 hours. The leaflet clarifies that the drug is not effective if pregnancy has already begun. Gedeon Richter reiterates that Postinor® is intended for occasional use and does not replace regular methods of contraception.

Contraindications and special precautions are detailed, including hypersensitivity to levonorgestrel or other ingredients, age below 16, severe liver disease, and breastfeeding. Patients are advised to consult a healthcare professional if they have any questions, experience side effects, or if pregnancy is suspected. The company also advises seeking medical consultation if a menstrual period is significantly delayed or if pregnancy is suspected after taking the medication.